Drug Pricing

The National Academy for State Health Policy (NASHP), with support from the Laura and John Arnold Foundation, today launched the Center for State Rx Drug Pricing. Building on the work of NASHP’s Pharmacy Costs Work Group over the past year, the Center will provide technical and strategic assistance to states, leverage legal and actuarial expertise […]

Read More
  • State Health Policy Blog

    In its May 30, 2017 decision Impression Products, Inc. v Lexmark International Inc., the Supreme Court ruled that patent law cannot be used to prevent the resale of products back into the United States. The Court case specifically concerned printer toner cartridges, but it is an important ruling in the context of the domestic policy […]

    Read More
  • As States Wage Battles on High Drug Prices, Drugmakers Fight Back May 18, 2017 Lembo targets ‘skyrocketing’ drug prices January 24, 2017 How can states tackle rising medication prices? January 11, 2017 Interfaith investor coalition pushes shareholder resolutions on drug prices, October 24, 2016 Politico Pulse mentioned the findings of the Pharmacy Costs Work Group, October 24, 2016 […]

    Read More
  • Publications

    Because the federal government has not been able to agree on an approach to constrain prescription drug prices, states need to address the problem. Study after study show how U.S. consumers pay the highest prices in the world for life-saving and life-enhancing drug treatments. The prices we pay may fund the research and development that […]

    Read More
  • State Health Policy Blog

    There is growing public pressure to find an effective way to address the rising prices of prescription drugs. Multiple drug price bills await action in Congress and more than 80 bills have been introduced in state legislatures in 2017. Among the variety of approaches aimed at managing drug prices, importation from other countries is an […]

    Read More
  • State Health Policy Blog

    With 80 bills introduced in 2017, there is a high level of interest in pharmaceutical pricing among state legislators. However, despite legislative sessions wrapping up, very few laws have been enacted. To date, bills have passed in Maryland, Montana, New Mexico, New York, and Utah. In 2016, Vermont led the way with a price transparency […]

    Read More
  • Pharmacy Costs Work Group – Model Legislation

    NASHP, with guidance from our Pharmacy Costs Work Group, has developed model legislation for states that wish to pursue the policy options outlined in our paper States and the Rising Costs of Pharmaceuticals: A Call to Action. States interested in this model legislation will have access to a legislator’s guide and additional background materials as […]

    Read More
  • Pharmaceutical prices are rising, driving up premiums and out of pocket costs. State budgets – that by law, have to be balanced- are reeling from high and unpredictable pharmaceutical price increases for Corrections, state employees and retirees, K-12 and public  university employees, and, of course,  Medicaid. To address rapidly rising prescription drug prices, purchasers and policy […]

    Read More
  • State Health Policy Blog

    Pharmaceutical prices are rising, driving up premiums and out-of-pocket costs. Today, 21 percent of spending in employer-sponsored plans goes to retail prescription drugs.[i] State budgets – that by law, have to be balanced- are reeling from high and unpredictable pharmaceutical increases for corrections, state employees and retirees, K-12 and public university employees, and, of course, […]

    Read More
  • State Health Policy Blog

    Congress has begun its Affordable Care Act (ACA) repeal effort and evolving replacement options are receiving considerable attention. NASHP is tracking issues that appear in multiple proposals and will provide state perspectives, including: How might they impact states? What might they cost? Have they been tried before in states and what did we learn from […]

    Read More